GLP-1 TV · News & media · views checked Oct 2026
Noom to offer prescriptions for weight-loss drugs
Our summary
According to the video, Noom is the latest company to move into the weight loss drug business, announcing that users will soon be able to get prescription obesity drugs through a new offering called NoomMed. The host frames it as a pivot for a company that has long focused on healthy body image, exercise and food. Yahoo Finance senior health care reporter Anjali Kamlani gives the details.
General education as published by the channel. Not medical advice, and not an endorsement.
Where semaglutide costs least today
The three cheapest partner programs for semaglutide, all in per month, checked weekly. Brand Ozempic and compounded versions are different products; each row says which it is.
What else the video covers
She says Noom previously had a partnership with Novo Nordisk around Saxenda, but this offering goes further. She places it in a wider shift, noting that Weight Watchers and telehealth platforms such as Ro have also joined, after earlier promoting behavioral and lifestyle changes like dieting, calorie tracking and exercise. She lists Wegovy as the only one approved for weight loss besides Saxenda, describes Ozempic and similar drugs as type 2 diabetes drugs, mentions Lilly's coming Mounjaro, and says Contrave is another option Noom will be able to offer.
She also raises a possible challenge: some employer-based health plans do not want to pay for these drugs. In her explanation, insurers resist covering weight loss because it can make the drugs lifestyle drugs, and she compares this to Viagra, which came out for one use and was later used for another. She says employers have already seen costs climb sharply, and adds that there is a lot of lobbying going on over whether coverage will expand.
Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.
Takeaways
The main points, in the order they come up. Tap a time to play from there.
- 0:00 Noom announced that users will soon be able to get prescription obesity drugs through its new NoomMed offering.
- 0:31 Kamlani says Noom previously partnered with Novo Nordisk on Saxenda, and that Weight Watchers and telehealth platforms like Ro have made similar shifts.
- 1:01 She says Wegovy and Saxenda are the approved weight loss options, while Ozempic-type drugs are approved for type 2 diabetes.
- 1:20 She says Lilly's Mounjaro is coming and that Contrave is another drug Noom will be able to offer.
- 1:52 Kamlani says some employer-based plans resist paying for these drugs because weight loss coverage puts them in the lifestyle drug category.
- 2:33 She says employers have already seen skyrocketing costs and that there is heavy lobbying over possible coverage.
What the video says
As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.
- Who is speaking
- News or media
Questions this video answers
What weight loss drugs will Noom offer through NoomMed?
According to the video, Noom members will be able to get prescription obesity drugs, with Wegovy, Saxenda and Contrave named as options. The reporter also mentions Lilly's Mounjaro as coming. She describes Ozempic-type drugs as type 2 diabetes medications.
Why is Noom's move into weight loss drugs seen as a pivot?
The host says Noom has always centered on healthy body image, exercise and food. The reporter adds that Noom, Weight Watchers and telehealth platforms like Ro are shifting from behavioral and lifestyle approaches to including GLP-1 drugs.
Why don't some employer health plans cover weight loss drugs?
Kamlani says insurers and employers push back because covering weight loss makes these a lifestyle drug, similar to Viagra. She adds that they had already seen skyrocketing costs from use of these drugs before pulling back.
Videos on the same question
The closest videos in the library by what is said in them, not by title.
Noom CEO on the launch of Noom GLP-1ᴿˣIn this short interview recorded on the New York Stock Exchange floor, the CEO of Noom says he took the job a little over a year ago because of the brand's reach and its mission to help people live better and longer.
Weight loss drugs like Wegovy access limited by insurance and Medicare coverageThis NBC News report looks at who can actually get the new weight loss drugs, and finds that cost and coverage are the main barriers.
FDA approves new weight-loss pill, FoundayoIn this Good Morning America segment, chief medical correspondent Dr. Tara Narula discusses a new once-a-day weight-loss pill from Eli Lilly called Foundayo, which the FDA has approved.
MOUNJARO: All Your Questions Answered!In this short update, Dr. Christy Risinger says Mounjaro (generic name tirzepatide) is approved for diabetes treatment and also causes weight loss.
Read next
Our guides closest to what this video covers, with prices checked weekly.
- Is Noom legit? What Noom's GLP-1 program costs, its reviews, and its record
Yes. Noom is a real company, and its Noom Med arm prescribes GLP-1s through licensed clinicians. As of October 2026 its own site prices the medication-included Noom GLP-1Rx plan, which is compounded semaglutide, at $129 for the first four weeks, then $279 a month billed as $837 every 12 weeks, though the FAQ on the same page says $249. Trustpilot scores Noom 4.5 across 67,088 reviews, mostly about its app, and we found no FDA warning letter naming it.
- GLP-1 patient assistance programs: what Lilly Cares and Novo's PAP actually cover
Both makers run free-drug programs for people with low income and no insurance or Medicare, but neither covers its weight-loss GLP-1. Novo Nordisk's Patient Assistance Program supplies Ozempic injections free to uninsured patients at or below 200% of the federal poverty level, and lists no Wegovy and no pills. Lilly Cares lists Trulicity as its only GLP-1: no Mounjaro, no Zepbound, no Foundayo. For weight loss, the realistic low-cost routes are the Medicare GLP-1 Bridge at $50 a month and the cash market.
- Mounjaro for weight loss, and why Zepbound exists
Mounjaro is tirzepatide approved for type 2 diabetes. Zepbound is the same molecule from the same maker, approved for weight management, and it goes to the same 15 mg. So unlike Ozempic and Wegovy, there is no dose ceiling pushing you from one to the other: the reason people move is coverage and cash price, not strength. Using Mounjaro for weight is off-label and a prescriber's decision. In the one head-to-head trial, tirzepatide beat semaglutide, 20.2% mean body-weight loss at 72 weeks against 13.7%.
Find more like it
Up next
More from this collection
Watched it? See what it costs.
Every GLP-1 program we track, ranked by what actually leaves your account.